… bevacizumab combined with first-line fluorouracil-leucovorin in patients with metastatic
colorectal cancer, bevacizumab … , and/or emesis No correlation with duration of exposure, history …

… for mCRC patients treated with first-line chemotherapy plus bevacizumab. PFS was defined
as the time from the beginning of the … Correlation of bevacizumabinduce hypertension and …

… The correlation between KRAS mutations and RR was expressed as odds ratio (OR) for
RR of wt … Role of Kras status in patients with metastatic colorectal cancer receiving first-line …

… of the medical records of 98 mCRC patients treated with first-line bevacizumab at the Hassan
II Regional Cancer Center (… Correlation between bevacizumab exposure and survival in …

… randomized clinical trials in first-line … patients treated with bevacizumab. But a higher rate
of grade 3 or 4 bleeding with the addition of bevacizumab to chemotherapy was not correlated …

… OS and PFS of the first line treatment were 24.4 and 6.5 months, … correlated with inferior
OS and PFS in patients with mCRC. The addition of bevacizumab to chemotherapy for patients …

… Our study demonstrates that AB appears to correlate with a significantly increased risk of
hypertension incidence of 31.1% (95% CI: 25.5-37.3) and an RR of 7.22 (95% CI: 3.3-15.7; p = …

… metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab was
… , aiming at investigating the correlation of VEGF SNPs with the efficacy of bevacizumab …

… patients withRASwild-type metastatic colorectal cancer, adding panitumumab, compared
with bevacizumab, to standard first-line … with left-sided tumors and in the overall population. …

… Proportionality assumptions were assessed using the Schoenfield residuals correlation and
log-log … The beneficial influence of bevacizumab in first-line treatment for mCRC has been …